MentionFox
Home › Executive changes › Biocryst Pharmaceuticals Inc
Leadership changes · BCRX · SEC Form 8-K, Item 5.02

Leadership changes at Biocryst Pharmaceuticals Inc (2026)

Before you join, sell to or invest in Biocryst Pharmaceuticals Inc

MentionFox check on Biocryst Pharmaceuticals Inc: no red flags found in 4 sources; 2 items to note (checked 14 November 2026). mentionfox.com/c/executive-changes/biocryst-pharmaceuticals

  • Note: Layoff plan disclosed Aug 2026 (filing)
  • Note: Layoff notice filed Aug 2026 (about 47 employees in AL) (state notice)

Check Biocryst Pharmaceuticals Inc before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Biocryst Pharmaceuticals Inc?

Who joined and who left Biocryst Pharmaceuticals Inc (BCRX)? 1 filing reported on 2026-01-23, each cited to the company's own filing.

As of November 14, 2026, Biocryst Pharmaceuticals Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 23, 2026 (Form 8-K, January 23, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Deerfield Mgmt, L.P. also filed stake reports on 19 other companies ↓

Sell to companies like Biocryst Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
Latest filing2026-01-23

Biocryst Pharmaceuticals Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-23. Every row below is cited to the filing it comes from, and this page adds each new change as Biocryst Pharmaceuticals Inc files it.

Layoffs on record: 2 filings or notices, latest 2026-08-04 (layoff filings and notices).

Also on the record for Biocryst Pharmaceuticals Inc

DateRecordFigureOur pageSource
November 10, 2026Stake report, Schedule 13G, by STATE STREET CORPORATION4.8% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by RA Capital Management, L.P.6.2% of the class5%+ stakesSource
August 7, 2026Stake report, Schedule 13G, by STATE STREET CORPORATION6% of the class5%+ stakesSource
May 12, 2026Stake report, Schedule 13G, by STATE STREET CORPORATION4.9% of the class5%+ stakesSource
April 29, 2026Stake report, Schedule 13G, by Vanguard Capital Management5.16% of the class5%+ stakesSource
March 26, 2026Stake report, Schedule 13G/A, by The Vanguard Group—5%+ stakesSource
February 12, 2026Stake report, Schedule 13G/A, by Deerfield Mgmt, L.P.6.81% of the class5%+ stakesSource
February 9, 2026Stake report, Schedule 13G, by STATE STREET CORPORATION5.3% of the class5%+ stakesSource
November 12, 2025Stake report, Schedule 13G, by RA Capital Management, L.P.7.3% of the class5%+ stakesSource
September 19, 2025Stake report, Schedule 13G, by Deerfield Mgmt, L.P.5.8% of the class5%+ stakesSource

Selling to them or working with them? See who runs Biocryst Pharmaceuticals Inc now and the warning signs.

Free to see. No signup.

Keep reading

More on Biocryst Pharmaceuticals Inc and the records around it.

Biocryst Pharmaceuticals Inc elsewhere on the record

Companies that share a holder

Want the whole picture on Biocryst Pharmaceuticals Inc?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Biocryst Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Biocryst Pharmaceuticals Inc covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-01-23Reportednot named in the filing8-K/A, 2026-01-23
Selling to Biocryst Pharmaceuticals Inc?

New leaders reset buying decisions — get the Full Report on Biocryst Pharmaceuticals Inc: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Biocryst Pharmaceuticals Inc

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at Biocryst Pharmaceuticals Inc, with the record behind each one.

Find candidates like senior executive at Biocryst Pharmaceuticals Inc

Every change, in the filing's words

Filed 2026-01-23 · 8-K/A

Reported

On October 14, 2025, BioCryst filed a Current Report on Form 8-K (the " Initial 8-K ") regarding the appointment of Jill C. Milne, Ph.D. to its board of directors (the " Board "), subject to certain conditions specified in the Merger Agreement.

Also stated in this filing

  • On January 23, 2026 (the "Closing Date"), BioCryst Pharmaceuticals, Inc., a Delaware corporation ("BioCryst") completed the transactions contemplated by the Agreement and Plan of Merger, dated as of October 14, 2025 (the "Merger Agreement"), by and among BioCryst, Axel Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BioCryst ("Merger Sub") and Astria Therapeutics, Inc., a Delaware corporation ("Astria").
  • On the Closing Date, Merger Sub merged with and into Astria (the "Merger"), with Astria surviving the Merger as a wholly owned subsidiary of BioCryst.
  • On the Closing Date, such conditions were satisfied and Dr. Milne's appointment to the Board became effective.
  • This Amendment No. 1 to the Initial 8-K is being filed to report that on January 20, 2026, the Board appointed Dr. Milne as a member of its Compensation and Science Committees, effective as of the Closing Date.

Tools for this story

Each opens in a new tab, filled in for Biocryst Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/biocryst-pharmaceuticals
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
What changed at the top of Biocryst Pharmaceuticals Inc?. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/biocryst-pharmaceuticals